6-month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)

被引：0
|
作者：
Straube, Andreas [1 ]
Broessner, Gregor [2 ]
Gaul, Charly [3 ]
Hamann, Xenia [4 ]
Hipp, Joachim [4 ]
Kraya, Torsten [5 ,6 ]
Neeb, Lars [7 ,8 ]
机构：
[1] Univ Hosp LMU, Dept Neurol, Munich, Germany
[2] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria
[3] Headache Ctr Frankfurt, Frankfurt, Germany
[4] Teva GmbH, Ulm, Germany
[5] Hosp Sankt Georg Leipzig gGmbH, Dept Neurol, Leipzig, Germany
[6] Univ Hosp, Headache Ctr Halle, Dept Neurol, Halle An Der Saale, Germany
[7] Helios Global Hlth, Berlin, Germany
[8] Charit Univ Med Berlin, Dept Neurol, Berlin, Germany
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-PO-2
引用
收藏
页码：260 / 260
页数：1
相关论文
共 50 条
  • [1] 6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [2] Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    [J]. NEUROLOGY, 2023, 100 (17)
  • [3] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    [J]. HEADACHE, 2023, 63 : 158 - 159
  • [4] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Andreas Straube
    Gregor Broessner
    Charly Gaul
    Xenia Hamann
    Joachim Hipp
    Torsten Kraya
    Lars Neeb
    [J]. The Journal of Headache and Pain, 24
  • [5] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [6] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    [J]. HEADACHE, 2022, 62 : 156 - 157
  • [7] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
    Driessen, M. T.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S. F.
    Seminerio, M. J.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J. M.
    [J]. HEADACHE, 2021, 61 : 141 - 141
  • [8] Real-world effectiveness of switching to fremanezumab from other CGRP pathway targeting mAbs: PEARL 3rd interim analysis
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Akcicek, H.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 371 - 372
  • [9] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
    Driessen, M.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S.
    Seminerio, M.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
  • [10] Effectiveness and tolerability of monoclonal antibodies targeting CGRP pathway for migraine prevention: Real-world data from the Migraine Registry (ReMig) in the Czech Republic
    Nezadal, T.
    Dolezal, T.
    Pejrilova, D.
    Turkova, B.
    Markova, J.
    Bartkova, A.
    Klecka, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
12345